What the labels say
Every GLP-1 weight label uses the same phrase: the medicine is approved for use together with a reduced-calorie diet and more physical activity [1][2][3][4]. The labels describe the medicine; they do not describe your diet. None of them states how many calories a person should eat, and NIDDK frames these medicines as a support for a healthy eating and activity plan rather than a substitute for one [8].
What “reduced-calorie diet” meant in the trials
Two things stand out. The common instruction was a deficit measured against each person’s estimated needs, not a single figure for everyone [1][2][3]. And the placebo groups received the same diet and activity advice [1][2], so the difference between groups reflects the medicine on top of counselling, not the diet alone. These were supervised research protocols; they are not targets for anyone reading this.
| Label and trials | Diet instruction | Activity and support |
|---|---|---|
| Wegovy®, most weight trials [1] | About 500 kcal a day below estimated needs | At least 150 minutes a week; counselling from the first dose |
| Wegovy®, Study 4 [1] | An initial low-calorie phase, then a reduced-calorie diet set by the trial | Activity that started lower and increased gradually |
| Zepbound®, Studies 1 and 2 [2] | About 500 kcal a day below estimated needs | At least 150 minutes a week; behaviour-change counselling |
| Zepbound®, Study 3 [2] | 12-week intensive lead-in with a set low-calorie intake; only those who lost at least 5% continued | Eight sessions with a dietitian or equivalent |
| Saxenda®, most weight trials [3] | About 500 kcal a day below estimated needs | At least 150 minutes a week |
| Saxenda®, one maintenance trial [3] | A low-calorie run-in before randomisation | Only those who lost at least 5% were randomised |
| Foundayo™, Trials 1 and 2 [4] | Instruction on a reduced-calorie diet; no number given in the label | At least 150 minutes a week |
Why PepLabo does not give you a number
A personal calorie target depends on things a website cannot see. The Dietary Guidelines say calorie needs vary with age, sex, height, weight and activity [7]. The nutrition advisory adds that the pace of dose increases and any calorie restriction should be guided by the individual’s needs, and that some people have reasons to lose weight faster or slower than others [5].
The medicine itself complicates the arithmetic. The EU product information describes semaglutide as reducing energy intake and hunger, with intake at a free-choice meal 35% lower than on placebo in one study [6], and the advisory reports large reductions in intake among people on these medicines [5]. Subtracting a standard deficit from an estimate, on top of a medicine that already cuts appetite, could leave someone eating far less than intended. That is why the number belongs with your clinician or a registered dietitian.
What a calorie estimate can and cannot tell you
PepLabo’s TDEE calculator estimates the energy you use in a day from the Mifflin-St Jeor equation and an activity level. It is useful for understanding where the trial phrase “500 kcal below needs” starts from. It is not a target: it is an estimate of energy used for a typical person with your measurements, and it says nothing about your medical conditions, medicines or how fast weight loss is appropriate for you.
Food tracking has a similar role. The advisory suggests that food logs or food photos help clinicians reassess intake and hydration during treatment [5]. The value is in showing what you actually eat, so a professional can judge whether it is enough.
When eating too little becomes the problem
- Nutrients: the advisory warns that a large, rapid fall in intake can leave people short of vitamins and minerals, and lists signs such as fatigue beyond what is expected, unusual hair loss, muscle weakness and slow wound healing [5].
- Muscle and bone: rapid weight loss frequently removes muscle as well as fat, and substantial, rapid loss has been linked to bone loss; strength training and enough protein are the advisory’s counterweights [5].
- Gallstones: the Wegovy® and Saxenda® labels note that substantial or rapid weight loss can increase the risk of gallstones, while gallbladder disease was still more common on the medicine after accounting for weight loss [1][3].
- Low blood sugar: people with diabetes using insulin or a sulfonylurea face a higher risk, which the labels address directly [1].
- Fluids: eating very little often means drinking little too, and the labels link fluid loss from vomiting or diarrhea to kidney injury [1][2].
Who can set a target, and what to ask
The advisory highlights registered dietitian nutritionists as the professionals trained to set an individual nutrition plan alongside GLP-1 treatment, adjusting it to tolerance, side effects and response [5]. Useful questions: Do I need a calorie target at all, or a protein and food-quality focus? How will we know if I am eating too little? Does my diabetes medicine change the plan? How often should we review it as the dose changes?
Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® is a registered trademark and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Today
- Feeling faint, shaky or confused while eating very little, especially on insulin or a sulfonylurea
Contact: Your prescriber; treat low blood sugar as you were taught
Wegovy® Medication Guide [1]
- Pain in the upper stomach, fever or yellowing of the skin or eyes
Contact: Your prescriber
Wegovy® Medication Guide [1]